Bio-Connect

InVivoPlus anti-mouse OX40 (CD134)

BP0031
Bio X Cell
ApplicationsWestern Blot, Other Application
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoPlus anti-mouse OX40 (CD134)
  • Delivery Days Customer
    7
  • Applications
    Western Blot, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    OX-86
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Rat
  • Isotype
    IgG1
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015,112(38):E5290-9. doi: 10.1073/pnas.1514418112
    Read this paper
  • Zander RA, Obeng-Adjei N, Guthmiller JJ, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015,17(5):628-41. doi: 10.1016/j.chom.2015.03.007
    Read this paper
  • Makkouk A, Joshi VB, Lemke CD, et al. Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res. 2015,3(4):389-98. doi: 10.1158/2326-6066.CIR-14-0173
    Read this paper
  • Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014,2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-T
    Read this paper
  • Guo Z, Wang X, Cheng D, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One. 2014,9(2):e89350. doi: 10.1371/journal.pone.0089350
    Read this paper
  • Krupnick AS, Lin X, Li W, et al. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest. 2014,124(3):1130-43. doi: 10.1172/JCI71359
    Read this paper
  • Hu Z, Zhang W, Usherwood EJ. Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. J Immunol. 2013,191(1):312-22. doi: 10.4049/jimmunol.1201773
    Read this paper
  • Kurche JS, Haluszczak C, McWilliams JA, et al. Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J Immunol. 2012,188(2):585-93. doi: 10.4049/jimmunol.1102550
    Read this paper
  • Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012,188(2):892-901. doi: 10.4049/jimmunol.1101373
    Read this paper
  • Murray SE, Polesso F, Rowe AM, et al. NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest. 2011,121(12):4775-86. doi: 10.1172/JCI44943
    Read this paper